Clinical Trial Update: Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 study evaluating gefitinib in combination with everolimus for stage IIIB/IV or recurrent non-small cell lung cancer. Results have been pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afinitor (everolimus)
• Iressa (gefitinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-01-21